|
Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health. Its business segments include the development of peptide-based therapeutics targeting obesity, rare diseases such as congenital hyperinsulinism and short bowel syndrome, and chronic inflammatory conditions. Main products and candidates in its pipeline include petrelintide, a long-acting amylin analog for weight loss; survodutide, a glucagon/GLP-1 receptor dual agonist for obesity and MASH, which is licensed to Boehringer Ingelheim; ZP9830, a Kv1.3 ion channel blocker for autoimmune diseases; ZP6590, a GIP receptor agonist for obesity; dasiglucagon, a glucagon analog for congenital hyperinsulinism; and glepaglutide, a GLP-2 analog for short bowel syndrome. The company serves patients with metabolic disorders and rare diseases. Notable partnerships include a collaboration and license agreement with Generate Biomedicines to develop protein therapeutics engineered with AI for metabolic diseases. Summarised from the company's own disclosures |
Industry Biotechnology | Homepage zealandpharma.com |
| Sector Healthcare | IR page — | |
|
Tags
obesity, metabolic health, peptide therapeutics, rare diseases, autoimmune diseases, clinical development, petrelintide, survodutide, ZP9830, ZP6590, dasiglucagon, glepaglutide, ZP8396, Boehringer Ingelheim, Generate Biomedicines
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 55.1% |
| ROI | 42.7% |
| ROIC | 47.0% |
| Profit margin | 70.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | 2.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | — |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | 9.215B | 62.69M | 342.78M | 103.98M | 292.56M |
| Net profit | 6.455B | -1.079B | -703.73M | -1.202B | -1.018B |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Zealand Pharma
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| OZEM | 3.04% | 50,254 | $ 1.699M | Nov 17, 2026 |
| HRTS | 0.44% | 5,223 | $ 243.479K | Aug 31, 2026 |
| DISV | 0.07% | 104,241 | $ 3.72M | Nov 12, 2026 |
| AVDS | 0.07% | 7,073 | $ 246.988K | Nov 16, 2026 |
| DXIV | 0.05% | 3,437 | $ 122.671K | Nov 12, 2026 |
| DFIS | 0.03% | 50,039 | $ 1.786M | Nov 12, 2026 |
| DFSI | 0.03% | 10,191 | $ 363.73K | Nov 12, 2026 |
| AVDE | 0.03% | 172,566 | $ 6.026M | Nov 16, 2026 |
| DFIC | 0.02% | 73,948 | $ 2.639M | Nov 12, 2026 |
| DFAX | 0.01% | 47,227 | $ 1.686M | Nov 12, 2026 |
| DFAI | 0.00% | 20,977 | $ 748.696K | Nov 12, 2026 |